These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 17655372)

  • 1. Clinical pharmacokinetics and use of infliximab.
    Klotz U; Teml A; Schwab M
    Clin Pharmacokinet; 2007; 46(8):645-60. PubMed ID: 17655372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
    Siddiqui MA; Scott LJ
    Drugs; 2005; 65(15):2179-208. PubMed ID: 16225377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab treatment of rheumatoid arthritis and Crohn's disease.
    Nahar IK; Shojania K; Marra CA; Alamgir AH; Anis AH
    Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy.
    Mori S
    Mod Rheumatol; 2007; 17(2):83-91. PubMed ID: 17437161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).
    Bondeson J; Maini RN
    Int J Clin Pract; 2001 Apr; 55(3):211-6. PubMed ID: 11351775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.
    Han PD; Cohen RD
    Drugs; 2004; 64(16):1767-77. PubMed ID: 15301561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on infliximab in Crohn disease and rheumatoid arthritis.
    Siddiqui MA; Scott LJ
    BioDrugs; 2006; 20(1):67-70. PubMed ID: 16573354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological profile of anti-human TNF alpha monoclonal antibody, infliximab (Remicade)].
    Sugita T
    Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):57-64. PubMed ID: 12617039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
    Onrust SV; Lamb HM
    BioDrugs; 1998 Nov; 10(5):397-422. PubMed ID: 18020611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
    N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Targeting therapy for inflammatory diseases by anti-TNFalpha biologics].
    Sugita T
    Yakugaku Zasshi; 2009 Jan; 129(1):19-24. PubMed ID: 19122432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
    Rutgeerts P; D'Haens G; Targan S; Vasiliauskas E; Hanauer SB; Present DH; Mayer L; Van Hogezand RA; Braakman T; DeWoody KL; Schaible TF; Van Deventer SJ
    Gastroenterology; 1999 Oct; 117(4):761-9. PubMed ID: 10500056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model.
    Ternant D; Pfister M; Le Tilly O; Mulleman D; Picon L; Willot S; Passot C; Bejan-Angoulvant T; Lecomte T; Paintaud G; Koch G
    Clin Pharmacokinet; 2022 Jan; 61(1):143-154. PubMed ID: 34351609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA; Villela R; Silverberg MS; Greenberg GR
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The underlying inflammatory chronic disease influences infliximab pharmacokinetics.
    Passot C; Mulleman D; Bejan-Angoulvant T; Aubourg A; Willot S; Lecomte T; Picon L; Goupille P; Paintaud G; Ternant D
    MAbs; 2016 Oct; 8(7):1407-1416. PubMed ID: 27589009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.